
Gian Carlo Mattiucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/717698/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radiation therapy for prostate cancer: What's the best in 2021. Urologia, 2022, 89, 5-15.	0.3	4
2	Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. Cancers, 2022, 14, 431.	1.7	7
3	The impact of radiomics in diagnosis and staging of pancreatic cancer. Therapeutic Advances in Gastrointestinal Endoscopy, 2022, 15, 263177452210815.	1.2	17
4	Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 661-667.	1.2	3
5	Functional results of exclusive interventional radiotherapy (brachytherapy) in the treatment of nasal vestibule carcinomas. Brachytherapy, 2021, 20, 178-184.	0.2	22
6	Artificial Intelligence in magnetic Resonance guided Radiotherapy: Medical and physical considerations on state of art and future perspectives. Physica Medica, 2021, 85, 175-191.	0.4	60
7	Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy. Diagnostics, 2021, 11, 72.	1.3	31
8	Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter caseâ€control study (PAULAâ€1). Cancer Medicine, 2020, 9, 7879-7887.	1.3	16
9	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers, 2020, 12, 1729.	1.7	26
10	Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer, 2019, 19, 569.	1.1	11
11	Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal caral carcinoma: A mono-institutional retrospective analysis. Journal of Contemporary Brachytherapy, 2019, 11, 21-27.	0.4	9
12	Magnetic resonance imaging (MRI) compared with computed tomography (CT) for interobserver agreement of gross tumor volume delineation in pancreatic cancer: a multi-institutional contouring study on behalf of the AIRO group for gastrointestinal cancers. Acta Oncológica, 2019, 58, 439-447.	0.8	13
13	Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial. British Journal of Radiology, 2019, 92, 20180422.	1.0	10
14	Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Translational Oncology, 2019, 12, 1-7.	1.7	18
15	EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis. Journal of Contemporary Brachytherapy, 2018, 10, 315-320.	0.4	13
16	Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model. Medical Oncology, 2018, 35, 146.	1.2	0
17	Magnetic Resonance, Vendor-independent, Intensity Histogram Analysis Predicting Pathologic Complete Response After Radiochemotherapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 765-774.	0.4	81
18	RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer. In Vivo, 2018, 31, 833-840.	0.6	4

#	Article	lF	CITATIONS
19	Beyond geometrical overlap: a Dosimetrical Evaluation of automated volumes Adaptation (DEA) in head and neck replanning. Technical Innovations and Patient Support in Radiation Oncology, 2017, 3-4, 1-6.	0.6	3
20	Perioperative HDR Brachytherapy for Reirradiation in Head and Neck Recurrences: Single-institution Experience and Systematic Review. Tumori, 2017, 103, 516-524.	0.6	28
21	Adjuvant radiotherapy with brachytherapy boost in soft tissue sarcomas. Journal of Contemporary Brachytherapy, 2017, 3, 256-262.	0.4	9
22	Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study. Future Oncology, 2016, 12, 779-787.	1.1	7
23	Reducing Heart dose during Left Breast Cancer Radiotherapy: Comparison among 3 Radiation Techniques. Tumori, 2016, 102, 184-189.	0.6	6
24	Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study. Anticancer Research, 2016, 36, 737-40.	0.5	21
25	Adjuvant Chemoradiotherapy in Gastric Cancer: A Pooled Analysis of the AIRO Gastrointestinal Group Experience. Tumori, 2015, 101, 91-97.	0.6	2
26	MITHRA – multiparametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a feasibility study. Journal of Contemporary Brachytherapy, 2015, 5, 336-345.	0.4	19
27	Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey. Oncology Reports, 2015, 34, 382-390.	1.2	1
28	A Phase I study of high-dose-rate intraluminal brachytherapy as palliative treatment in extrahepatic biliary tract cancer. Brachytherapy, 2015, 14, 401-404.	0.2	22
29	Endoscopy-guided brachytherapy for sinonasal and nasopharyngeal recurrences. Brachytherapy, 2015, 14, 419-425.	0.2	22
30	Can automation in radiotherapy reduce costs?. Acta OncolÃ ³ gica, 2015, 54, 1282-1288.	0.8	6
31	Radioprotective effect of calcium channel blockers against late rectal bleeding in prostate cancer. Radiologia Medica, 2014, 119, 343-7.	4.7	3
32	Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial. BioMed Research International, 2014, 2014, 1-8.	0.9	2
33	Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience. Radiation Oncology, 2014, 9, 198.	1.2	48
34	Multi-institutional Pooled Analysis on Adjuvant Chemoradiation in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 911-917.	0.4	55
35	Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiation Oncology, 2014, 9, 45.	1.2	18
36	Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. Critical Reviews in Oncology/Hematology, 2014, 90, 58-67.	2.0	20

#	Article	IF	CITATIONS
37	Clinical validation of atlas-based auto-segmentation of pelvic volumes and normal tissue in rectal tumors using auto-segmentation computed system. Acta Oncológica, 2013, 52, 1676-1681.	0.8	39
38	Long-term Analysis of Gemcitabine-based Chemoradiation after Surgical Resection for Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2013, 20, 423-429.	0.7	12
39	Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 87-92.	0.8	17
40	Development of a Modelling to Correlate Site and Diameter of Brain Metastases with Hippocampal Sparing Using Volumetric Modulated Arc Therapy. BioMed Research International, 2013, 2013, 1-6.	0.9	4
41	Automatic delineation for replanning in nasopharynx radiotherapy: What is the agreement among experts to be considered as benchmark?. Acta Oncológica, 2013, 52, 1417-1422.	0.8	49
42	Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. Anticancer Research, 2013, 33, 2785-9.	0.5	21
43	Quality of Life and Toxicity of Stereotactic Radiotherapy in Pancreatic Tumors: A Case Series. Cancer Investigation, 2012, 30, 149-155.	0.6	23
44	Recurrence in region of spared parotid gland in patient receiving definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A case report. Acta Oncológica, 2012, 51, 1095-1099.	0.8	2
45	Intensity-modulated Radiotherapy With Simultaneous Integrated Boost to Dominant Intraprostatic Lesion. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 158-162.	0.6	43
46	Early Proctoscopy is a Surrogate Endpoint of Late Rectal Toxicity in Prostate Cancer Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, e191-e195.	0.4	19
47	Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Medical Oncology, 2012, 29, 3478-3483.	1.2	44
48	Effect of Whole Pelvic Radiotherapy for Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy and Long-Term Androgen Deprivation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e721-e726.	0.4	37
49	Postoperative Intensity Modulated Radiation Therapy in High Risk Prostate Cancer: A Dosimetric Comparison. Medical Dosimetry, 2011, 36, 231-239.	0.4	11
50	Low-Dose Hyperradiosensitivity: Is There a Place for Future Investigation in Clinical Settings?. International Journal of Radiation Oncology Biology Physics, 2010, 76, 535-539.	0.4	22
51	Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study. Acta OncolÃ ³ gica, 2010, 49, 418-422.	0.8	6
52	Integration between <i>in vivo</i> dosimetry and image guided radiotherapy for lung tumors. Medical Physics, 2009, 36, 2206-2214.	1.6	24
53	Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis. Radiotherapy and Oncology, 2009, 92, 176-183.	0.3	84
54	Chemoradiation and brachytherapy in biliary tract carcinoma: Long-term results. International Journal of Radiation Oncology Biology Physics, 2006, 64, 483-488.	0.4	55

#	Article	IF	CITATIONS
55	The Prognostic Effect of Clinical Staging in Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2005, 12, 145-151.	0.7	36
56	Radiotherapy in cT3 Prostatic Carcinoma: Retrospective Comparison between Neoadjuvant and Adjuvant Hormonotherapy. Urologia Internationalis, 2004, 72, 21-27.	0.6	0
57	5-fluorouracil–based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1454-1460.	0.4	27
58	An application of visible human database in radiotherapy: tutorial for image guided external radiotherapy (TIGER). Radiotherapy and Oncology, 2004, 70, 165-169.	0.3	12
59	Cost- and time-sparing simplified conformal therapy for prostate cancer: is it feasible?. International Journal of Radiation Oncology Biology Physics, 1998, 42, 65-71.	0.4	4